Secretary Thompson received both his B.S. in 1963 and his J.D. in 1966 from the University of Wisconsin-Madison. He is a member of the District of Columbia and Wisconsin Bars.
Jim Hitchin, CEO of SpectraScience said, "Secretary Thompson brings to the Company a wealth of knowledge of heath care in this Country. We look forward to working with him to further early cancer detection. We all know that early detection saves lives."
SpectraScience has developed a multi-patented and proprietary WavSTAT(TM) Optical Biopsy System that is used by physicians to diagnose tissue to determine if it is normal, pre-cancerous, or cancerous within seconds. The WavSTAT(TM) System is currently approved by the FDA for use in detecting pre-cancer and cancer in the colon. A new application for detecting pre-cancers in the throat, sometimes called Barrett's esophagus, is being tested in a clinical trial. Cancer of the esophagus is more than 90% fatal and may develop as a result of chronic heartburn or GERD. Esophageal cancer is growing five times faster than all other cancers.
This news release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. These
forward-looking statements involve risks and uncertainties that may cause
SpectraScience's actual results to differ materially from the results
discussed in the forward-looking statements. Readers are urged to carefully
review and consider the various disclosures made by SpectraScience in this
news release, the Form 10-KSB and in SpectraScience's
|SOURCE SpectraScience, Inc.|
Copyright©2007 PR Newswire.
All rights reserved